Senior Director, Clinical Biomarker Operations Revolution Medicines, Inc.Senior Director, Clinical Biomarker OperationsRedwood City, CA$244,000–$305,000 / yearThe Opportunity: Revolution Medicines is seeking a strategic and experienced leader to serve as Senior Director, Clinical Biomarker Operations, responsible for leading the operational execution of biomarker and companion diagnostic (CDx) strategies across early- and late-stage clinical development programs. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, CMC Regulatory Revolution Medicines, Inc.Associate Director, CMC RegulatoryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: As part of our expanding organization, we seek a strategic and hands-on Associate Director, CMC Regulatory who will be responsible for executing CMC regulatory strategies to support clinical development, marketing authorizations, and lifecycle management of RevMed's pipeline compounds/products.
Associate Director, Clinical Operations Compliance & Training Revolution Medicines, Inc.Associate Director, Clinical Operations Compliance & TrainingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Associate Director, Finance Systems - IT BillionToOneAssociate Director, Finance Systems - ITMenlo Park, CA$192,932–$235,806 / yearAdministerand maintain the company's IT General Controls (ITGCs) across in scope financial systems, implementing the ITGC framework, including logical access, change management, and computer operations controls across all in-scope financial systems. This is a senior individual contributor and people-leadership role that sits at the intersection of finance, compliance, and technology-responsible for ensuring our systems infrastructure is scalable, audit-ready, and aligned with the demands of a public company operating under SOX Section 404(b).
Director Of Enterprise Sales Collectly, Inc.Director Of Enterprise SalesSan Francisco, CA$330,000–$390,000 / yearCollectly applies artificial intelligence to automate workflows, accelerate cash flow, and modernize the patient financial experience; enabling healthcare organizations to operate more efficiently and focus on delivering care. This leader will manage a team of experienced Enterprise Account Executives and be responsible for driving predictable revenue performance through stronger pipeline discipline, sharper enterprise deal strategy, and rigorous execution.
Regional Insights And Engagement Director, Lung, Southeast Revolution Medicines, Inc.Regional Insights And Engagement Director, Lung, SoutheastRedwood City, CARemote$231,000–$254,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed's US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Senior Director, Head Of Transactions & Partnering Revolution Medicines, Inc.Senior Director, Head Of Transactions & PartneringRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role partners closely with Business Development leadership and cross-functional stakeholders across Research, Development, Commercial, Finance, Legal, Intellectual Property, and Executive Management to advance high-priority opportunities from initial assessment through successful execution.
Associate Director, Biostatistics Clinical Late Stage Revolution Medicines, Inc.Associate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Statistical Programming Revolution Medicines, Inc.Associate Director, Statistical ProgrammingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function.
Director Of IT BillionToOneDirector Of ITUnion City, CA$214,369–$267,962 / yearAt BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. Unity Confirm enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne's Fetal Cell Capture Technology.
Executive Director, Computational Systems Biology Revolution Medicines, Inc.Executive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Sr. Manager / Associate Director, Quality Audits Personalis, IncSr. Manager / Associate Director, Quality AuditsFremont, CA$165,000–$210,000 / yearReporting directly to the Director of Quality Assurance, this individual is responsible for the strategic oversight, design, and execution of the global Internal Audit program, as well as leading the readiness and management of all External Audits (including regulatory inspections and accreditation assessments).The successful candidate will have strong leadership skills and possess extensive experience managing Quality Management Systems (QMS) within highly regulated environments, driving compliance, governance, and continuous improvement across the organization with a high degree of autonomy. Root Cause & Investigation Leadership: Provide expert guidance and lead cross-functional investigation teams in executing comprehensive root cause analyses for CAPAs, deviations, and non-conformances stemming from internal and external audits.
Associate Director, Global Omnichannel Solutions Delivery Revolution Medicines, Inc.Associate Director, Global Omnichannel Solutions DeliveryRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The individual will play a critical role in supporting global expansion by establishing scalable solutions, enabling adoption of global platforms, and ensuring new capabilities, brands, and regions can be added efficiently without rework or fragmentation.
Director, Program Management Revolution Medicines, Inc.Director, Program ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Director, Program Management partners with the Project Team Leader (PTL) on the translation of program strategy into an efficient execution plan; they understand the competitive landscape and clinical context to manage the cross-functional dependencies and connections.
Director, Market Access Analytics And Enablement DanaherDirector, Market Access Analytics And EnablementSunnyvale, CARemote$185,000–$215,000 / yearAssume full ownership of the development, refinement, and implementation of strategy for data analytics and enablement function including: development of market access enablement tools; market insights/trends generation; healthcare coding analyses (diagnosis codes, billing codes, code modifiers, etc.); pricing and fee schedule evaluations; payer coverage dashboards; team dashboards; analytics frameworks; operational tools; and utilization of AI-based tools to inform decision-making and accelerate business outcomes. Success in this position requires an opportunity mindset, strong executive presence, demonstrated leadership capabilities, innovative thinking to drive actionable insights and tools, the ability to communicate complex insights clearly across senior and cross-functional stakeholders, and disciplined execution to meet critical deadlines.
Associate Director, Regulatory Systems Revolution Medicines, Inc.Associate Director, Regulatory SystemsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. This individual will serve as the business owner for key regulatory systems and partner closely with Regulatory Affairs, Regulatory Operations, IT, Quality, Clinical, and external vendors to deliver scalable, compliant, and efficient business solutions.
Associate Director, Business Operations Revolution Medicines, Inc.Associate Director, Business OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The role is ideal for a Associate Director -level professional who thrives on execution, can drive several projects in parallel, can navigate a matrix environment, and brings strong project leadership, communication and change management experience.
Director, Clinical Study Management Eikon Therapeutics, Inc.Director, Clinical Study ManagementMillbrae, CA$226,000–$273,000 / yearThis role will require a minimum of 3 days a week of onsite presence (or more as business needs require) in either of our Jersey City, New Jersey or Millbrae, California offices to ensure effective management and high-performance delivery of clinical studies. The Director will manage all aspects of clinical operations study management for assigned Eikon clinical studies, and be responsible for exquisite inhouse execution of all such clinical trials and oversight of requisite clinical vendors.
Senior Director, Head Of Search & Evaluation Revolution Medicines, Inc.Senior Director, Head Of Search & EvaluationRedwood City, CARemote$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Working in close partnership with leaders across Research, Development, Commercial, Corporate Strategy, Portfolio Management, and Executive Management, this individual will lead the company's search and evaluation activities across discovery and clinical-stage opportunities.
Director, Regulatory Affairs Companion Diagnostics (Cdx) Revolution Medicines, Inc.Director, Regulatory Affairs Companion Diagnostics (Cdx)Redwood City, CA$211,000–$264,000 / yearRequired Skills, Experience and Education: Advanced degree or bachelor's degree in life sciences, molecular biology, biomedical engineering, pharmacy, medicine, or related scientific discipline with a minimum of 12+ years of pharmaceutical, biotechnology, diagnostics, or combination product experience, including at least 8 years in Regulatory Affairs supporting companion diagnostics or in vitro diagnostics. This individual will serve as the regulatory lead for companion diagnostic development programs, partnering closely with Clinical Development, Translational Medicine, Biomarker Sciences, Regulatory Science, Commercial, and external diagnostic partners to ensure successful co-development and global registration of therapeutic products and associated companion diagnostics.
Director of Commercial Marketing Mendaera, Inc.Director of Commercial MarketingSan Mateo, CA$190,000–$219,000 / yearDevelop and continuously refine clinical value propositions for each procedure and specialty Focalist competes in—grounded in procedure-level insights and translated into messaging that drives adoption and utilization across physician, care team, and hospital audiences. Develop and execute specialty-level market development programs—peer-to-peer events, case observation programs, symposia, and conference presence—designed to build procedural competency and expand the base of trained, active Focalist users.
Regional Insights And Engagement Director, Northeast Revolution Medicines, Inc.Regional Insights And Engagement Director, NortheastRedwood City, CARemote$231,000–$254,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Sales, Medical Affairs, Market Access, and Commercial Operations & Business Analytics teams to ensure alignment of RevMed's US commercialization strategy; Uncovers, prioritizes, and communicates market insights, challenges/barriers, and solutions to the organization.
Director, Regulatory Affairs (US Filing Lead) Revolution Medicines, Inc.Director, Regulatory Affairs (US Filing Lead)Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Director, Global Patient Safety Operations Revolution Medicines, Inc.Director, Global Patient Safety OperationsRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Work collaboratively and cross-functionally to ensure timely and accurate completion of expedited and periodic reports (e.g., DSUR, PBRER), aggregate safety reports, and REMS/RMP analyses, and other safety deliverables.
Director, Global Lead, PI And Digital Twin AVEVA Group PlcDirector, Global Lead, PI And Digital TwinSan Leandro, CA$168,900–$281,700 / yearAVEVA's Global Practice and Services organization (700+ engineers, consultants, program managers and solution architects) is looking for a proven practice leader to own and scale our PI Data Infrastructure & Digital Twin delivery practice worldwide. Solution Portfolio and Technical Excellence: Develop comprehensive offerings spanning AVEVA PI DI, AVEVA Predictive Analytics, AVEVA Operations Control, AIM and CONNECT - integrating real-time (OT) and non-real-time (IT) systems at scale.
Associate Director, Quality Validation Revolution Medicines, Inc.Associate Director, Quality ValidationRedwood City, CA$186,000–$233,000 / yearAs a key member of the Quality organization, the Associate Director, Quality Validation partners closely with cross-functional teams within Pharmaceutical Development & Manufacturing (PDM) and external partners to develop and maintain robust validation strategies, support commercial manufacturing and product disposition activities, drive continuous improvement, and ensure consistent execution of validation programs across the global external manufacturing network. The Opportunity: The Associate Director, Quality Validation is responsible for providing strategic quality leadership and oversight of validation programs supporting Drug Substance (DS), Drug Product Intermediate (DPI), Drug Product (DP), packaging, and distribution activities across the company's global network of CDMOs, packaging partners, and suppliers.
Director, Regulatory Affairs - US Filing Lead Revolution Medicines, Inc.Director, Regulatory Affairs - US Filing LeadRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Global Strategic Account Director DanaherGlobal Strategic Account DirectorSan Francisco, CARemote$150,000–$180,000 / yearResolve complex or unusual business problems by applying advanced critical thinking-coordinates company-wide resources to provide comprehensive solutions based on the entire product and services portfolio across Cytiva. The amount and availability of any bonus, commission, benefits, or any other form of compensation and benefits that are allocable to a particular employee remains in the Company's sole discretion unless and until paid and may be modified at the Company's sole discretion, consistent with the law.
Senior Director, Compliance Training Revolution Medicines, Inc.Senior Director, Compliance TrainingRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner closely with Learning & Development, Corporate Communications, Legal, HR, regional compliance staff (U.S., Europe, and Asia), and business stakeholders to ensure effective deployment, localization, communication, and reinforcement of training programs.
Associate Director, Revenue Accounting And Finance Revolution Medicines, Inc.Associate Director, Revenue Accounting And FinanceRedwood City, CA$186,000–$233,000 / yearPrepare and analyze monthly product revenue and gross-to-net close activities, including the calculation, recording, and monitoring of gross-to-net accruals and related reserve balances for prompt pay discounts, copay and patient assistance programs, returns, Medicaid, Medicare Part D, 340B, VA/DoD, and other forms of variable consideration. Manage the day-to-day partnership with the external government pricing consultant, including coordinating required data submissions, reviewing government pricing calculations and related outputs, and supporting accuracy and compliance across government channels, including Medicaid, Medicare Part D, 340B, and VA/FSS programs.
Associate Director, Clinical Quality Assurance Revolution Medicines, Inc.Associate Director, Clinical Quality AssuranceRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director, Clinical Data Management Revolution Medicines, Inc.Director, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Media Director, Programmatic Syneos Health IncAssociate Media Director, ProgrammaticSan Francisco, CATogether we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. Selecting us as an employer secures a career in which you're guaranteed to: Collaborate with passionate problem solvers Partner with the most diverse team of experts in the industry.
NewSenior Director - TeraWave Ground Terminals Blue Origin Enterprises LPSenior Director - TeraWave Ground TerminalsSan Francisco, CA$317,388–$444,342.15 / yearand/or transports placardable amounts of hazardous materials by ground in any vehicle on a public road while in commerce, may be subject to additional Federal Motor Carrier Safety Regulations including: Driver Qualification Files, Medical Certification (obtained before onboarding), Road Test, Hours of Service, Drug and Alcohol Testing, vehicle inspection requirements, CDL requirements (if applicable) and hazardous materials transportation/shipping training. Required for Certain Job Profiles: Drivers who operate Commercial Motor Vehicles with a Gross Vehicle Weight (GVW), Gross Vehicle Weight Rating (GVWR) or combination of power unit and trailer that meets or exceeds 10,001 lbs.
Director, Systems Engineering (Hybrid) CeribellDirector, Systems Engineering (Hybrid)Sunnyvale, CA$216,000–$283,000 / yearThe Ceribell System is a novel, point-of-care electroencephalography ("EEG") platform specifically designed to address the unmet needs of patients in the acute care setting, and is being used in hundreds of community hospitals, large academic facilities and major IDN's across the country. Position Overview: We are seeking a highly technical Director of Systems Engineering to lead the core electrical hardware, systems, and software development of our next-generation products, while providing ongoing systems engineering leadership for our current core products.
Director, Systems Engineering (Hybrid) Ceribell, IncDirector, Systems Engineering (Hybrid)Sunnyvale, CA$216,000–$283,000 / yearThe Ceribell System is a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting, and is being used in hundreds of community hospitals, large academic facilities and major IDN's across the country. Position Overview : We are seeking a highly technical Director of Systems Engineering to lead the core electrical hardware, systems, and software development of our next-generation products, while providing ongoing systems engineering leadership for our current core products.
Director, System Software Engineering - Metropolis Accelerated And Inferencing Software NvidiaDirector, System Software Engineering - Metropolis Accelerated And Inferencing SoftwareSanta Clara, CAYou bring strong intuition for modern architectures (e.g., transformers, diffusion, and VLMs); deep experience tuning on NVIDIA GPUs (kernels, memory, and latency/efficiency trade-offs)/SOCs; and a proven record of delivering robust, low-latency inference at scale. Drive strategic implementations of TensorRT, VLLM, and other accelerated frameworks for inference solutions for Edge and Enterprise devices: Lead Accelerated Computing efforts and solutions for key Metropolis verticals.
NewSenior Director, US Compliance Revolution Medicines, Inc.Senior Director, US ComplianceRedwood City, CA$244,000–$305,000 / yearAreas of focus include: Serve as the strategic compliance advisor to Commercial, Medical Affairs, Market Access, Patient Services, and other field-facing functions by proactively identifying compliance risks, enabling compliant business solutions, and embedding compliance into key business decisions throughout commercialization and product launch. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Director, Molecular Pathology, Translational Sciences, Translational Research. Revolution Medicines, Inc.Director, Molecular Pathology, Translational Sciences, Translational Research.Redwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: As a Director, Molecular Pathology, you will be a key member of a cross-functional Translational Sciences Team, reporting to the Senior Director and Head of Translational Sciences within Translational Research and will: Biomarker Strategy: Define and execute molecular and digital pathology-driven biomarker strategies.
Senior Director, Molecule Global Regulatory Lead Revolution Medicines, Inc.Senior Director, Molecule Global Regulatory LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provide strategic oversight for the planning and execution of major regulatory submissions, including INDs, CTAs, amendments, expedited designation requests, marketing applications, and lifecycle submissions.
Senior Director, Clinical Data Management Revolution Medicines, Inc.Senior Director, Clinical Data ManagementRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Senior Director, Clinical Operations, Global Clinical Vendor Contracts & Budgets Revolution Medicines, Inc.Senior Director, Clinical Operations, Global Clinical Vendor Contracts & BudgetsRedwood City, CA$244,000–$305,000 / yearThe leadership role ensures alignment with strategic objectives, regulatory requirements, and study timelines as well as bringing deep expertise in managing complex trials, contract negotiations, budget development, risk management, and cross-functional collaboration to contribute to the highest quality with on time delivery of RevMed's clinical studies. A member of the Clinical Operations team Leading the Contracts and Outsourcing for all vendor relationships within Clinical Development, the Sr Director Global Vendor Outsourcing will lead the strategic identification and selection process with the teams for vendors and CROs, including scope specifications for clinical programs, and will work closely with the Sr.
Director, Alliance Management Revolution Medicines, Inc.Director, Alliance ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Executive Director, Global Patient Safety Quality And Compliance - Pharmacovigilance Revolution Medicines, Inc.Executive Director, Global Patient Safety Quality And Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Director of IP Operations Cooley LLPDirector of IP OperationsCA$220,000–$270,000 / yearInterface with other firm departments to determine best practices and implement efficient workflow and integration points that will make the daily functions of the IP Services more efficient and will enable better collaboration as it relates to intakes and transfers, disengagements, electronic file management, and supporting marketing and business development initiatives. Moderate and facilitate meetings comprised of IP partners, associates, practice group professionals and other administrative personnel; set and manage realistic expectations for project deliverables; put ideas into a practical context and coordinate efforts of multi-disciplinary teams to meet project deliverables.
NewAssociate Director, Clinical Operations Revolution Medicines, Inc.Associate Director, Clinical OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Senior Director, Global CMC Lead Revolution Medicines, Inc.Senior Director, Global CMC LeadRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director, Global CMC Lead will provide cross-functional leadership and accountability for defining and executing integrated CMC strategies across development-stage and late-stage small molecule programs.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.